Opinion

Video

AUA 2024: Outlining BOND-003 Data for NMIBC Therapy

Author(s):

Gary Steinberg, MD, FACS

Expert urologist reviews the BOND-003 study, discussing its design, interim outcomes, safety and efficacy data, and the potential for cretostimogene grenadenorepvec to provide a durable response in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following question(s):

      • Focusing on the BOND-003 study, please review the study design, key interim outcomes, and safety and efficacy data.
      Related Videos
      4 experts in this video
      Case 1: A 79-Year-Old Man With Non–Muscle-Invasive Bladder Cancer
      4 experts in this video
      Non–Muscle Invasive-Bladder Cancer Overview
      Laura Davis, MD, on link between microplastics and bladder cancer
      Laura Davis, MD, on link between microplastics and bladder cancer
      Rebecca A. Campbell, MD, answers a question during a Zoom video interview
      Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
      Expert discusses the NMIBC trials landscape
      John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
      John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
      Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
      Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
      Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
      Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
      Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
      Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
      Related Content
      FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
      May 21st 2025

      FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk

      Hannah Clarke
      The committee voted 4-5 in opposition of a favorable benefit-risk profile.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
      May 15th 2025

      Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

      Tracey L. Krupski, MD Jeunice Owens-Walton, MD
      "The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
      Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
      December 7th 2021

      Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

      Urology Times staff
      “It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      May 9th 2025

      Durvalumab plus BCG significantly improves DFS in NMIBC

      Benjamin P. Saylor Hannah Clarke
      The data are to be presented at an upcoming medical conference.
      Physical function and frailty measures offer distinct insights in patients with bladder cancer
      May 7th 2025

      Physical function and frailty measures offer distinct insights in patients with bladder cancer

      Hannah Clarke
      Data showed that physical function and self-reported frailty assessments were poorly correlated.
      © 2025 MJH Life Sciences

      All rights reserved.